Read by QxMD icon Read


Kate J Robson, Danielle Clucas, Robin Filshie, Harshal Nandurkar
We describe the case of a 35-year-old man presenting with thrombotic microangiopathy (TMA) and renal impairment following, as he later disclosed, intravenous injection of oral formulation tamper-resistant extended-release oxycodone hydrochloride (Oxycontin). Recurrent misuse of this agent was associated with relapsing TMA despite treatment with terminal complement inhibitor eculizumab. Cases of TMA have been reported in the USA in association with intravenous misuse of extended-release oxymorphone (Opana ER) after the introduction of a new non-crushable formulation in 2012...
July 17, 2017: BMJ Case Reports
E Jokinen, A Heino, T Karipohja, M Gissler, R Hurskainen
OBJECTIVE: To determine the safety and effectiveness of female sterilisation in the Finnish population. DESIGN: A national register-based study using record linkage. SETTING: National data from Finland. SAMPLE: A total of 16 272 female sterilisations performed in 2009-2014. METHODS: The Register of Sterilisations was linked with the Hospital Discharge Register, Termination of Pregnancy Register, and the Medical Birth Register in order to investigate the occurrence of re-sterilisations, other surgical operations, and unwanted pregnancies after sterilisation, per method...
May 2, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, Andrew Wirth, John F Seymour, Michael S Hofman, Rodney J Hicks
In the treatment of diffuse large B-cell lymphoma, a persistently positive [18 F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%...
February 2017: Haematologica
Leelavathi Basava, Priyankur Roy, V Anusha Priya, Shubhashri Srirama
INTRODUCTION: Sterilization at caesarean section is usually performed by the modified Pomeroy's technique. Application of Falope rings and Filshie clips may also be used for tubal sterilization at caesarean section, and these techniques are also used during laparoscopy or minilaparotomy. OBJECTIVES: The main objective of the study was to evaluate the failure rates, complications, technical difficulties and reversibility of the Falope ring application for tubal sterilization as compared to the traditional modified Pomeroy's technique used during caesarean sections...
October 2016: Journal of Obstetrics and Gynaecology of India
Theresa A Lawrie, Regina Kulier, Juan Manuel Nardin
BACKGROUND: This is an update of a review that was first published in 2002. Female sterilisation is the most popular contraceptive method worldwide. Several techniques exist for interrupting the patency of fallopian tubes, including cutting and tying the tubes, damaging the tube using electric current, applying clips or silicone rubber rings, and blocking the tubes with chemicals or tubal inserts. OBJECTIVES: To compare the different tubal occlusion techniques in terms of major and minor morbidity, failure rates (pregnancies), technical failures and difficulties, and women's and surgeons' satisfaction...
August 5, 2016: Cochrane Database of Systematic Reviews
Melita Kenealy, Nigel Patton, Robin Filshie, Andrew Nicol, Shir-Jing Ho, Mark Hertzberg, Tony Mills, Ian Prosser, Emma Link, Linda Cowan, Diana Zannino, John F Seymour
Single agent azacitidine or immunomodulatory drugs are effective in myelodysplastic syndrome (MDS), with differing target mechanisms and toxicities. Objectives of this ALLG MDS3 study in clinically advanced MDS, AMML and low blast AML were to establish safety, response and quality of life of azacitidine and thalidomide. Patients received azacitidine (75mg/m2 /d sc 7days every 28 days), and oral thalidomide up to 100mg/d for maximum 12months. Eighty patients registered; median age 68 years (range 42-82), 49% IPSS int2-high...
February 2017: Leukemia & Lymphoma
A Minchom, R Punwani, J Filshie, J Bhosle, K Nimako, J Myerson, R Gunapala, S Popat, M E R O'Brien
BACKGROUND: Dyspnoea is one of the commonest symptoms of lung cancer. Opioids can reduce dyspnoea. This study investigates acupuncture for relief of breathlessness in lung cancer. METHODS: We performed a single-centre, randomised phase II study of 173 patients with non-small cell lung cancer or mesothelioma with dyspnoea score of ≥4 on visual analogue scale (VAS). Randomisation was to acupuncture alone (A), morphine alone (M) or both (AM). Acupuncture was administered at upper sternal, thoracic paravertebral, trapezius trigger points and LI4...
July 2016: European Journal of Cancer
Harry J Iland, Marnie Collins, Ken Bradstock, Shane G Supple, Alberto Catalano, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Lynda J Campbell, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore, John Bashford, John F Seymour
BACKGROUND: Initial treatment of acute promyelocytic leukaemia traditionally involves tretinoin (all-trans retinoic acid) combined with anthracycline-based risk-adapted chemotherapy, with arsenic trioxide being the treatment of choice at relapse. To try to reduce the relapse rate, we combined arsenic trioxide with tretinoin and idarubicin in induction therapy, and used arsenic trioxide with tretinoin as consolidation therapy. METHODS: Patients with previously untreated genetically confirmed acute promyelocytic leukaemia were eligible for this study...
September 2015: Lancet Haematology
Thomas E Lew, Chan Y Cheah, Dennis A Carney, H Miles Prince, Max Wolf, Ali Bazargan, E Henry Januszewicz, Robin Filshie, David Westerman, John F Seymour, Constantine S Tam
Despite its efficacy in prospective trials, full dose fludarabine, cyclophosphamide and rituximab (FCR) may be too toxic for elderly patients with chronic lymphocytic leukemia (CLL) in clinical practice. We retrospectively reviewed the impact of dose reductions in FCR therapy on the outcomes of 42 consecutive patients aged 65-87 (median 72) years. Despite a median cumulative fludarabine dose reduction of 50% from full dose, the objective response and complete response rates were 86% and 38% respectively (frontline 94%/59%; previously treated 80%/24%)...
May 2016: Leukemia & Lymphoma
Theresa A Lawrie, Regina Kulier, Juan Manuel Nardin
BACKGROUND: This is an update of a review that was first published in 2002. Female sterilisation is the most popular contraceptive method worldwide. Several techniques exist for interrupting the patency of fallopian tubes, including cutting and tying the tubes, damaging the tube using electric current, applying clips or silicone rubber rings, and blocking the tubes with chemicals or tubal inserts. OBJECTIVES: To compare the different tubal occlusion techniques in terms of major and minor morbidity, failure rates (pregnancies), technical failures and difficulties, and women's and surgeons' satisfaction...
2015: Cochrane Database of Systematic Reviews
Alison Michelle Mumme, Jamie Cham
INTRODUCTION: Tubal occlusion is a common form of contraception. Filshie clips have been widely used for tubal occlusion since their introduction. Reports of Filshie clip migration are rare. We describe what we believe to be the first reported case of a patient with multiple groin hernias associated with migration of a Filshie clip. CASE PRESENTATION: We report the case of 56-year-old Caucasian woman who presented with a tender right groin lump. She had undergone a right-sided inguinal hernia repair 3 years earlier...
September 7, 2015: Journal of Medical Case Reports
Jeremy Ong, David Yeung, Robin Filshie, Timothy P Hughes, Harshal Nandurkar
Imatinib is generally well tolerated, but gastric antral vascular ectasia (GAVE) remains a rare but significant complication of imatinib therapy. Whilst this complication has been described in other disease settings, only one other case of GAVE has been reported in a chronic myeloid leukaemia (CML) patient receiving imatinib. Herein, we present three CML patients with GAVE complicating imatinib therapy. In all cases, GAVE resolved only with cessation of imatinib. This confirms a causal relationship between GAVE and imatinib...
November 2015: International Journal of Hematology
David T Yeung, Michael P Osborn, Deborah L White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra K Hiwase, Mark Hertzberg, Anthony P Schwarer, Robin Filshie, Christopher K Arthur, Yiu Lam Kwan, Judith Trotman, Cecily J Forsyth, John Taper, David M Ross, Jennifer Beresford, Constantine Tam, Anthony K Mills, Andrew P Grigg, Timothy P Hughes
The Therapeutic Intensification in De Novo Leukaemia (TIDEL)-II study enrolled 210 patients with chronic phase chronic myeloid leukemia (CML) in two equal, sequential cohorts. All started treatment with imatinib 600 mg/day. Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL, imatinib 800 mg/day was given. Patients were then assessed against molecular targets: BCR-ABL1 ≤10%, ≤1%, and ≤0.1% at 3, 6, and 12 months, respectively. Cohort 1 patients failing any target escalated to imatinib 800 mg/day, and subsequently switched to nilotinib 400 mg twice daily for failing the same target 3 months later...
February 5, 2015: Blood
Mackereth Peter, Bardy Joy, Filshie Jacqueline, Finnegan-John Jennifer, Molassiotis Alexander
OBJECTIVE: To explore the experience of breast cancer patients who either received acupuncture or were allocated to the control group. METHODS: Focus group/interviews nested within our multi-site randomised controlled trial. Participants were recruited from the standard care and experimental arm. The interviews/focus groups were transcribed and analysed thematically. RESULTS: Of the 302 eligible participants 13% (n = 40) contributed to the focus groups/interviews, across three study sites in the UK...
November 2014: Complementary Therapies in Clinical Practice
S Kamel, L Horton, L Ysebaert, M Levade, K Burbury, S Tan, M Cole-Sinclair, J Reynolds, R Filshie, S Schischka, A Khot, S Sandhu, M J Keating, H Nandurkar, C S Tam
The BTK (Bruton's tyrosine kinase) inhibitor ibrutinib is associated with an increased risk of bleeding. A previous study reported defects in collagen- and adenosine diphosphate (ADP)-dependent platelet responses when ibrutinib was added ex vivo to patient samples. Whereas the collagen defect is expected given the central role of BTK in glycoprotein VI signaling, the ADP defect lacks a mechanistic explanation. In order to determine the real-life consequences of BTK platelet blockade, we performed light transmission aggregometry in 23 patients receiving ibrutinib treatment...
April 2015: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
K D Cummins, S M Jane, S Ninkovic, S Nikovic, A Bazargan, R Filshie, G Sutrave, M Hertzberg, A Scott, S Lane, C K Yannakou, D Ritchie, J D'Rozario, J Black, K Bavishi, A Wei
No abstract text is available yet for this article.
2014: Blood Cancer Journal
Jason D Lickliter, Kerry Taylor, Jeff Szer, Andrew Grigg, Christopher Arthur, Timothy P Hughes, Simon Durrant, Robin Filshie, Ian Irving, Michael Seldon, Jennifer Ellacott, Andrew W Boyd, James D'Rozario, Kim Rooney, Kevin Lynch, Ken Bradstock
We report long-term results in 40 patients with Philadlephia chromosome-positive (Ph+) acute leukemia who received an imatinib monotherapy window to evaluate in vivo effects on BCR-ABL signaling prior to induction chemotherapy. The first 25 patients (cohort 1) received the LALA-94 protocol without further imatinib (newly diagnosed Ph+ acute lymphoblastic leukemia [ALL]) or induction chemotherapy followed by single-agent imatinib. Subsequent patients (cohort 2) continued imatinib concurrently with either LALA-94 (newly diagnosed Ph + ALL) or other intensive chemotherapy regimens...
March 2015: Leukemia & Lymphoma
Anneloes N J Huijgens, Céline M J G Lardenoije, Helen J M M Mertens
OBJECTIVE: To analyze data on sterilization and refertilization procedures that took place at Orbis Medical Center in Sittard, a hospital in the south of the Netherlands. STUDY DESIGN: Retrospective cohort study of surgical tubal sterilizations performed on 966 patients for contraception between 2002 and 2011, and of 19 patients who underwent refertilization between 2002 and 2012. The main outcome measures were complications and failure rates of sterilization, motives for refertilization and pregnancy rates after refertilization...
April 2014: European Journal of Obstetrics, Gynecology, and Reproductive Biology
S Lingaratnam, A Mellerick, L J Worth, M Green, S Guy, S Kirsa, M Slavin, W Renwick, R Filshie, K A Thursky
BACKGROUND: Although Australian consensus guidelines support the use of ambulatory care strategies for management of adult patients with low-risk neutropenic fever (NF), few centres have successfully implemented viable programmes. AIMS: To study the feasibility of an early discharge programme for adult patients with low-risk NF and assess organisational factors likely to influence successful implementation across participating Victorian hospitals. METHODS: Four hospitals participated in an organisational readiness assessment preceding selection of a pilot site for programme implementation...
September 2013: Internal Medicine Journal
David M Ross, Susan Branford, John F Seymour, Anthony P Schwarer, Christopher Arthur, David T Yeung, Phuong Dang, Jarrad M Goyne, Cassandra Slader, Robin J Filshie, Anthony K Mills, Junia V Melo, Deborah L White, Andrew P Grigg, Timothy P Hughes
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients who had sustained undetectable minimal residual disease (UMRD) by conventional quantitative polymerase chain reaction (PCR) on imatinib for at least 2 years. Patients stopped imatinib and were monitored frequently for molecular relapse. At 24 months, the actuarial estimate of stable treatment-free remission was 47...
July 25, 2013: Blood
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"